ADV

Serial Number 97383925
601

Registration Progress

Application Filed
Apr 27, 2022
Under Examination
Approved for Publication
Published for Opposition
Registered

Re-Apply for This Trademark

This trademark is no longer active. You may be able to file a new application for the same or similar mark.
Mark: ADV
Previous Owner: Mercury Pharma Group Limited
Classes: 005

Trademark Image

ADV

Basic Information

Serial Number
97383925
Filing Date
April 27, 2022
Abandonment Date
May 1, 2023
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
601
Status Date
May 2, 2023
Classes
005

Rights Holder

Mercury Pharma Group Limited

03
Address
Capital House
85 King William Street
London EC4N7BL
GB

Ownership History

Mercury Pharma Group Limited

Original Applicant
03
London GB

Legal Representation

Attorney
Meghna Prasad

Application History

16 events
Date Code Type Description Documents
May 2, 2023 MAB1 E ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT Loading...
May 2, 2023 ABN1 O ABANDONMENT - EXPRESS MAILED Loading...
May 1, 2023 EXAR I TEAS EXPRESS ABANDONMENT RECEIVED Loading...
Apr 27, 2023 LOPR P LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN Loading...
Mar 24, 2023 LOPT I LETTER OF PROTEST EVIDENCE FORWARDED Loading...
Feb 2, 2023 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
Jan 24, 2023 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Jan 24, 2023 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
Jan 24, 2023 CNSL R SUSPENSION LETTER WRITTEN Loading...
Jan 24, 2023 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Jan 24, 2023 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Jan 24, 2023 GNEA F EXAMINERS AMENDMENT E-MAILED Loading...
Jan 24, 2023 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Jan 18, 2023 DOCK D ASSIGNED TO EXAMINER Loading...
May 3, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Apr 30, 2022 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
A full line of pharmaceuticals for the treatment of depression, hypertension, malaria, metastatic prostate cancer, benign prostatic hyperplasia, partial seizures in adults with epilepsy, attention deficit hyperactivity disorder (ADHD), heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, acute enterocolitis, duodenal ulcer, and irritable bowel syndrome being irritable colon, spastic colon, mucous colitis; anti-inflammatory medicines, and immunosuppressive agents, namely, corticosteroids; pharmaceutical preparations for the treatment of cancers and abnormal cells; all of the foregoing excluding pharmaceutical preparations acting on the peripheral or central nervous system, surgical kits comprised of medical and surgical apparatus and instruments, and surgical implants comprised of human and animal tissue; all of the foregoing excluding anti-infective pharmaceutical preparations
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005